News
IBIO
1.450
+1.40%
0.020
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 15h ago
Weekly Report: what happened at IBIO last week (0720-0724)?
Weekly Report · 1d ago
Weekly Report: what happened at IBIO last week (0713-0717)?
Weekly Report · 07/20 09:52
iBio Updates Governance Deadlines for 2026 Annual Meeting
TipRanks · 07/17 21:31
Weekly Report: what happened at IBIO last week (0706-0710)?
Weekly Report · 07/13 09:54
Weekly Report: what happened at IBIO last week (0629-0703)?
Weekly Report · 07/06 09:56
Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal
NASDAQ · 07/02 14:09
iBio Is Maintained at Buy by Chardan Capital
Dow Jones · 07/02 09:45
iBio Price Target Maintained With a $5.00/Share by Chardan Capital
Dow Jones · 07/02 09:45
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO)
TipRanks · 07/02 06:40
Buy Rating Reiterated on iBio as IBIO-610 Data Underscore Differentiated Efficacy; $5 Price Target Maintained
TipRanks · 07/01 19:15
IBio's IBIO-610 Achieves Near-Complete Activin E Inhibition In Obese Primate Study
NASDAQ · 07/01 12:38
iBio Highlights Promising New Preclinical Obesity Antibody Data
TipRanks · 07/01 11:59
iBio says single-dose IBIO-610 achieves 98% Activin E inhibition through eight weeks in obese primate study
PUBT · 07/01 11:34
iBio announces new preclinical data from IBIO-610 study
TipRanks · 07/01 11:30
iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate
Benzinga · 07/01 11:08
IBIO REPORTS SINGLE DOSE OF IBIO-610 ACHIEVED NEAR-COMPLETE ACTIVE ACTIVIN E INHIBITION THROUGH EIGHT WEEKS IN OBESE NHP STUDY
Reuters · 07/01 11:04
iBio says single-dose IBIO-610 cuts active Activin E 98% through eight weeks in obese primate study
PUBT · 07/01 11:02
Weekly Report: what happened at IBIO last week (0622-0626)?
Weekly Report · 06/29 09:53
Weekly Report: what happened at IBIO last week (0615-0619)?
Weekly Report · 06/22 09:59
More
Webull provides a variety of real-time IBIO stock news. You can receive the latest news about Ibio through multiple platforms. This information may help you make smarter investment decisions.
About IBIO
iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.